Millennium Management’s Artelo Biosciences ARTL Stock Holding History

Millennium Management’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-44	Closed	-$6K	–	6876
2021 Q4	$6K	Buy	+44	New	+$8.69K	﹤0.01%	6677

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCA

Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Millennium Management's ARTL Position: Q1 2022 in Review

Millennium Management sold out of Artelo Biosciences (ARTL) in Q1 2022, closing a stake of 44 shares — an estimated $6K sold.

Millennium Management first reported a position in ARTL in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 18 funds tracked by Wall St. Rank hold ARTL as of Q1 2022.

Millennium Management reported no remaining Artelo Biosciences position as of Q1 2022 after selling out during the quarter.
Millennium Management sold 44 Artelo Biosciences shares in Q1 2022, an estimated $6K.
Millennium Management first reported a position in Artelo Biosciences in Q4 2021 and held it in 1 quarter.
Millennium Management's Artelo Biosciences position peaked at $6K in Q4 2021.
18 funds tracked by Wall St. Rank held Artelo Biosciences as of Q1 2022.

Based on Millennium Management's 13F filing for Q1 2022, filed 16 May 2022.